antviral/sarcoma

This work was supported in part by grants from the National Institutes of Health. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the isolation and propagation of a novel human herpesvirus derived from AIDS-associated Kaposi's Sarcoma cells, diagnostic methods

BACKGROUND OF THE INVENTION Trisodium phosphonoformate (PFA trisodium salt, Foscarnet), a pyrophosphate analogue, inhibits HIV reverse transcriptase (HIV, RT) with an IC.sub.50 near 1 .mu.M, and also inhibits several herpesvirus DNA polymerases including the DNA polymerase of Cytomegalovirus (CMV).

The present invention, which results from work carried out by the Institut Pasteur or by direction of the latter, has for its object a compound of complexed heteropolyanions which contains tungsten combined with antimony. The invention is more particularly concerned with a compound and its

FIELD OF THE INVENTION The field of the invention is antiviral compositions and methods of generating the same. BACKGROUND OF THE INVENTION Although viruses are the causative agents of a number of human and animal diseases, there is currently a paucity of antiviral agents effective in ablating or

BACKGROUND OF THE INVENTION The present invention relates to the therapeutic application of human chorionic gonadotropin (HCG) for its previously unappreciated, immune-potentiating properties in human patients. More specifically, the present invention relates to the use of HCG in treatment of and

BACKGROUND OF THE INVENTION In spite of several years of detailed investigation there has been only minor success with current anti-HIV/AIDS therapies for various reasons, including cross-resistance to protease inhibitors, problems and lack of effective clinical outcomes with gene transfer methods,

REFERENCE TO RELATED APPLICATIONS The present application is the national stage under 35 U.S.C. 371 of international application PCT/IL99/00704, filed Dec. 28, 1999 which designated the United States, and which international application was published under PCT Article 21 (2) in the English

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to treatment and prevention of Human Immunodeficiency Virus (HIV) by using a live genetically altered HIV virus vaccine. 2. Description of the Prior Art To the best of this inventor's knowledge, no prior art employing a